Connection details for the SENS-601 Program Day are as follows: Date and time: September 22, 2026, at 2:30pm CET (8:30am ET) ...
Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, ...
MINNEAPOLIS, MN – September 16, 2026 – Evia Bio, Inc., a life science company advancing next-generation cryopreservation ...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders’ Equity Compliance
September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused ...
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and ...
Electra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ...
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular ...
As Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, ...
With just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a ...
After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously ...
Discover innovative financial strategies and expert guidance from leading bioscience finance executives at this first-ever West Coast forum.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results